Announcement on the 2018 Profit Distribution Plan
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2019-015
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2018 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
l
Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") 2018 Profit Distribution Plan is based on 2018 year-end share capital ,344,083, 828 shares, cash dividends 3.0 yuan (tax included) are distributed for every 10 shares, and the total cash dividends to all shareholders registered on the equity registration date are 103,225,148.40 yuan (tax included).
l
Review Procedure: This profit distribution plan has been reviewed and approved at the 10th meeting of the 10th Board of Directors of the Company, and still needs to be submitted to the 2018 Annual General Meeting of Shareholders of the Company for review.
1. 2018 The main contents of the profit distribution plan
are audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of 2018 is ,588,502,101.59 yuan. Net profit in accounting statement of parent company ,433,675,496.73 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 43,367,549.67 yuan, plus undistributed profit 658,978,622.43 yuan at the beginning of the year, minus 2017 annual cash dividend 34,408,382.80 yuan, and the distributable profit for this year is 1,014,878,186.69 yuan.
Company plans to make cash distribution in 2018 . Based on 2018 year-end share capital ,344,083, 828 shares, it will distribute cash dividends 3.0 yuan (including tax) per 10 shares, and the total amount of cash dividends to all shareholders registered on the equity registration date will be , 225,148.40 yuan (tax included).
2018 year will not carry out provident fund to increase share capital.
2. Profit Distribution Plan Description
( 1 ) Implementation of the Company's Cash Dividend Policy
The Articles of Association of the Company stipulate that the accumulated profits distributed in cash in the last three years shall not be less than the 30% of the average annual distributable profits realized in the last three years.
The proportion of the company's accumulated profits distributed in cash in the last three years to the average annual distributable profits realized in the last three years is 89.59 , which is in line with the cash dividend policy stipulated in the company's "Articles of Association.
( 2 ) Company's Development
At present, the company is in the stage of accelerated development. The company will speed up the project of Guizhou Huangpinggu Longmingchuan Cement Co., Ltd. On the basis of acquiring the 100% equity of the company, the company will continue to invest about 6.5 .3 billion yuan to build a new dry cement production line with a daily output of of 4500 tons of cement clinker (with waste heat for power generation); the total investment for the project of producing 20 .7 billion solid preparations in Jinxi production base of Jianfeng pharmaceutical industry with an annual output of is expected to be 50146 .49 million yuan, and 2019 will carry out plant construction and equipment procurement. Anhui Zhongwang, a subsidiary of Shanghai Beika, a subsidiary of Jianfeng Pharmaceutical Company, will carry out the second phase of technological transformation to build an intermediate and bulk drug base for the company's pharmaceutical sector. In addition, spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor new drug "DPT " has entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. The development of the above-mentioned business requires large financial support.
( 3 ) Considering that the company has invested a lot in technological transformation and new product development in 2018 , in order to maintain the company's stable operation and support the company's long-term development, Taking into account the short-term and long-term interests of shareholders, the board of directors approved the above-mentioned 2018 profit distribution plan.
( 4 ) The company will hold a 2018 annual performance and cash dividend explanation meeting to communicate and exchange with investors on the company's 2018 annual performance and cash dividend matters, and timely answer investors' concerns.
3. Review Procedure
2019 4 26 , the company held the 184 meeting of the 10th 183 of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on his behalf, comply with the relevant provisions of the "Company Law" and the "Articles of Association" of the company, and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the company's 2018 profit distribution plan was deliberated and approved with 9 votes in favor, 0 votes against, and 0 abstentions.
2018 Annual General Meeting of Shareholders for deliberation. When the company convenes the general meeting of shareholders, it will provide investors with online voting facilities.
2018 :
, and the independent director agreed that the company should use 2018 year-end share capital ,344,083, 828 as the base, A cash dividend of 3.0 yuan (tax included) will be distributed to 10 shares of , and the total amount of cash dividends distributed to all shareholders registered on the date of equity registration is ,148.40 yuan (tax included), No provident fund will be converted into share capital in 2018 .
. The profit distribution plan is formulated according to the actual operating results and financial situation of the company 2018 , and in combination with the actual needs of the company's future business development. The retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company and the long-term interests of shareholders, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors believe that the plan complies with the relevant provisions of the Company's Articles of Association on profit distribution and the actual operating conditions of the Company.
3 , the company's board of directors considered and approved the above profit distribution plan. The independent directors believe that the convening, convening, and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the "Articles of Association", and are legal and effective; and agree to submit the plan to the company's 2018 Annual General Meeting for deliberation.
5. Related Risk Tips
This profit distribution plan must be submitted to the company's 2018 annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April 30, 2019
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page